{
  "ticker": "PHVS",
  "company_name": "Pharvaris N.V.",
  "success": true,
  "trials": [
    {
      "nct_id": "NCT05834777",
      "title": "Prevention of Intradialytic Hypotension by Inhibiting Bradykinin B2 Receptor",
      "status": "RECRUITING",
      "phase": "PHASE3",
      "condition": "Intradialytic Hypotension",
      "start_date": "2023-12-11",
      "completion_date": "2026-04-01",
      "enrollment": 0,
      "sponsor": "Vanderbilt University Medical Center"
    },
    {
      "nct_id": "NCT07266805",
      "title": "Study of Oral Deucrictibant XR Tablet for Prophylaxis and Deucrictibant IR Capsule for On-Demand Treatment of Angioedema Attacks in Adults With Acquired Angioedema Due to C1 Inhibitor Deficiency",
      "status": "RECRUITING",
      "phase": "PHASE3",
      "condition": "Acquired Angioedema Due to C1-Inhibitor Deficiency (AAE-C1-INH)",
      "start_date": "2025-10-16",
      "completion_date": "2027-06",
      "enrollment": 0,
      "sponsor": "Pharvaris Netherlands B.V."
    },
    {
      "nct_id": "NCT04618211",
      "title": "Dose-ranging Study of Oral PHA-022121 for Acute Treatment of Angioedema Attacks in Patients With Hereditary Angioedema",
      "status": "COMPLETED",
      "phase": "PHASE2",
      "condition": "Hereditary Angioedema, Hereditary Angioedema Type I, Hereditary Angioedema Type II, Hereditary Angioedema Types I and II, Hereditary Angioedema Attack, Hereditary Angioedema With C1 Esterase Inhibitor Deficiency, Hereditary Angioedema - Type 1, Hereditary Angioedema - Type 2, C1 Esterase Inhibitor Deficiency, C1 Inhibitor Deficiency",
      "start_date": "2021-02-03",
      "completion_date": "2023-03-01",
      "enrollment": 0,
      "sponsor": "Pharvaris Netherlands B.V."
    },
    {
      "nct_id": "NCT05396105",
      "title": "Extension Study of Oral PHA-022121 for Acute Treatment of Angioedema Attacks in Patients With Hereditary Angioedema",
      "status": "ENROLLING_BY_INVITATION",
      "phase": "PHASE2, PHASE3",
      "condition": "Hereditary Angioedema, Hereditary Angioedema Type I, Hereditary Angioedema Type II, Hereditary Angioedema Types I and II, Hereditary Angioedema Attack, Hereditary Angioedema With C1 Esterase Inhibitor Deficiency, Hereditary Angioedema - Type 1, Hereditary Angioedema - Type 2, C1 Esterase Inhibitor [C1-INH] Deficiency, C1 Esterase Inhibitor Deficiency, C1 Esterase Inhibitor, Deficiency of, C1 Inhibitor Deficiency, Hereditary Angioedema Type III, Hereditary Angioedema (HAE), Hereditary Angioedema Type I and II",
      "start_date": "2022-12-28",
      "completion_date": "2027-06",
      "enrollment": 0,
      "sponsor": "Pharvaris Netherlands B.V."
    },
    {
      "nct_id": "NCT05047185",
      "title": "Dose-ranging Study of Oral PHA-022121 for Prophylaxis Against Angioedema Attacks in Patients With Hereditary Angioedema Type I or Type II",
      "status": "COMPLETED",
      "phase": "PHASE2",
      "condition": "Hereditary Angioedema, Hereditary Angioedema Type I, Hereditary Angioedema Type II, Hereditary Angioedema Types I and II, Hereditary Angioedema Attack, Hereditary Angioedema With C1 Esterase Inhibitor Deficiency, Hereditary Angioedema - Type 1, Hereditary Angioedema - Type 2, C1 Esterase Inhibitor Deficiency, C1 Inhibitor Deficiency",
      "start_date": "2022-04-19",
      "completion_date": "2025-06-30",
      "enrollment": 0,
      "sponsor": "Pharvaris Netherlands B.V."
    },
    {
      "nct_id": "NCT06669754",
      "title": "Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAE",
      "status": "RECRUITING",
      "phase": "PHASE3",
      "condition": "Hereditary Angioedema (HAE)",
      "start_date": "2024-12-01",
      "completion_date": "2026-08",
      "enrollment": 0,
      "sponsor": "Pharvaris Netherlands B.V."
    },
    {
      "nct_id": "NCT06343779",
      "title": "Study of Oral Deucrictibant Soft Capsule for On-Demand Treatment of Angioedema Attacks in Adolescents and Adults With Hereditary Angioedema",
      "status": "COMPLETED",
      "phase": "PHASE3",
      "condition": "Hereditary Angioedema, Hereditary Angioedema Type I, Hereditary Angioedema Type II, Hereditary Angioedema Types I and II, Hereditary Angioedema Attack, Hereditary Angioedema With C1 Esterase Inhibitor Deficiency, Hereditary Angioedema - Type 1, Hereditary Angioedema - Type 2, C1 Esterase Inhibitor [C1-INH] Deficiency, C1 Esterase Inhibitor Deficiency, C1 Esterase Inhibitor, Deficiency of, C1 Inhibitor Deficiency, Hereditary Angioedema - Type 3, Hereditary Angioedema Type III",
      "start_date": "2024-02-26",
      "completion_date": "2025-10-17",
      "enrollment": 0,
      "sponsor": "Pharvaris Netherlands B.V."
    },
    {
      "nct_id": "NCT06679881",
      "title": "Long-Term, Open-label Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAE",
      "status": "RECRUITING",
      "phase": "PHASE3",
      "condition": "Hereditary Angioedema (HAE)",
      "start_date": "2025-02-01",
      "completion_date": "2028-12",
      "enrollment": 0,
      "sponsor": "Pharvaris Netherlands B.V."
    }
  ],
  "summary": {
    "total_trials": 8,
    "by_phase": {
      "PHASE3": 5,
      "PHASE2": 2,
      "PHASE2, PHASE3": 1
    },
    "by_status": {
      "RECRUITING": 4,
      "COMPLETED": 3,
      "ENROLLING_BY_INVITATION": 1
    },
    "active_trials": 5,
    "completed_trials": 3,
    "conditions": [
      "Acquired Angioedema Due to C1-Inhibitor Deficiency (AAE-C1-INH)",
      "Hereditary Angioedema (HAE)",
      "Hereditary Angioedema, Hereditary Angioedema Type I, Hereditary Angioedema Type II, Hereditary Angioedema Types I and II, Hereditary Angioedema Attack, Hereditary Angioedema With C1 Esterase Inhibitor Deficiency, Hereditary Angioedema - Type 1, Hereditary Angioedema - Type 2, C1 Esterase Inhibitor Deficiency, C1 Inhibitor Deficiency",
      "Hereditary Angioedema, Hereditary Angioedema Type I, Hereditary Angioedema Type II, Hereditary Angioedema Types I and II, Hereditary Angioedema Attack, Hereditary Angioedema With C1 Esterase Inhibitor Deficiency, Hereditary Angioedema - Type 1, Hereditary Angioedema - Type 2, C1 Esterase Inhibitor [C1-INH] Deficiency, C1 Esterase Inhibitor Deficiency, C1 Esterase Inhibitor, Deficiency of, C1 Inhibitor Deficiency, Hereditary Angioedema - Type 3, Hereditary Angioedema Type III",
      "Hereditary Angioedema, Hereditary Angioedema Type I, Hereditary Angioedema Type II, Hereditary Angioedema Types I and II, Hereditary Angioedema Attack, Hereditary Angioedema With C1 Esterase Inhibitor Deficiency, Hereditary Angioedema - Type 1, Hereditary Angioedema - Type 2, C1 Esterase Inhibitor [C1-INH] Deficiency, C1 Esterase Inhibitor Deficiency, C1 Esterase Inhibitor, Deficiency of, C1 Inhibitor Deficiency, Hereditary Angioedema Type III, Hereditary Angioedema (HAE), Hereditary Angioedema Type I and II",
      "Intradialytic Hypotension"
    ],
    "lead_stage": "phase_3"
  },
  "provenance": {
    "source": "ClinicalTrials.gov API v2",
    "timestamp": "2026-01-29T12:20:57.700811",
    "search_query": "Pharvaris N.V.",
    "url": "https://clinicaltrials.gov/search?term=Pharvaris+N.V."
  }
}